The Impact of Estradiol Dynamics During the Menopause Transition on Depression Risk: A Narrative Review of Estradiol's Neurobiological Mechanisms.
Level 5 - mechanism / opinion, no new human data
Narrative review of neurobiological mechanisms and clinical observations without systematic review or meta-analysis.
PubMed 41679526 · doi:10.1016/j.biopsych.2026.02.002
What was done
This narrative review synthesized literature examining the relationship between estradiol (E2) dynamics during the menopausal transition (MT) and the risk of depressive symptoms or perimenopausal-onset major depressive episodes (PO-MDE). The authors outlined clinical impacts of fluctuating E2, insights from supplementary E2 therapy, and evaluated four mechanistic domains: neurotransmitter signaling, neuroimmune function, brain glucose metabolism, and synaptogenesis.
What was found
The abstract reports no quantitative data or effect sizes. It qualitatively describes that shifting E2 dynamics during MT influence brain health and mood vulnerability through neuromodulatory pathways involving neurotransmission, immune regulation, cerebral glucose utilization, and synaptic plasticity.
Why it matters
Clarifying the neurobiological pathways linking estradiol fluctuations to perimenopausal depression helps frame why this reproductive transition is a window of vulnerability and highlights targets for endocrine and psychotropic interventions.
Limits
As a narrative review, the methodology lacks systematic search protocols, predefined inclusion criteria, and formal quality assessments of cited studies. The abstract provides no primary human data, quantitative outcomes, or details regarding the number and types of studies analyzed.
Cited by
- supports Declining estrogen levels lead to depression.